Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2.
Higuchi, Y., Suzuki, T., Arimori, T., Ikemura, N., Mihara, E., Kirita, Y., Ohgitani, E., Mazda, O., Motooka, D., Nakamura, S., Sakai, Y., Itoh, Y., Sugihara, F., Matsuura, Y., Matoba, S., Okamoto, T., Takagi, J., Hoshino, A.(2021) Nat Commun 12: 3802-3802
- PubMed: 34155214 
- DOI: 10.1038/s41467-021-24013-y
- Primary Citation of Related Structures:  
7DMU - PubMed Abstract: 
SARS-CoV-2 has mutated during the global pandemic leading to viral adaptation to medications and vaccinations. Here we describe an engineered human virus receptor, ACE2, by mutagenesis and screening for binding to the receptor binding domain (RBD). Three cycles of random mutagenesis and cell sorting achieved sub-nanomolar affinity to RBD ...